Method for inducing myocardial cells to differentiate and mature by using granulocyte colony stimulating factor
By using granulocyte colony stimulating factor (G-CSF) and other inhibitors during cardiomyocyte differentiation, the problem of cardiomyocyte immaturity under traditional methods is solved, the efficient maturation of cardiomyocytes is achieved, and the treatment of heart disease cells is promoted. feasibility.
Patent Information
- Application Number
- CN202310634145.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-31
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2043-05-31
Smart Images

Figure CN119060944A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of cell preparations, and in particular to a method for inducing myocardial cell differentiation and maturation by utilizing granulocyte colony stimulating factor (G-CSF). Background Art
[0002] In recent years, there have been more and more studies on stem cell differentiation. Human pluripotent stem cells (hPSCs) include embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), which have been successfully differentiated into myocardial cells (CMs) in vitro. Myocardial cells differentiated from stem cells have broad application prospects and are often used in regenerative therapy related to heart disease, exploration of the mechanism of hereditary heart disease, discovery of new drugs, and evaluation of drug cardiac toxicity safety.
[0003] Although the cardiomyocytes differentiated by the traditional 2D differentiation method have similar molecular, structural and functional characteristics to cardiomyocytes, the main problem of this technology is that compared with adult CMs, the hPSC-CMs induced by the traditional 2D differentiation scheme are immature in structure and function (Chen et al., 2019), mainly in terms of morphology, metabolism, calcium handling and electrophysiology, and proliferation (Liao et al., 2021). These immature characteristics seriously hinder the application prospects of hPSC-CMs. There are also many researchers who imitate the natural environment of cardiomyocytes in the body and simulate different 3D conditions to promote their maturation. For example, Kadota et al. found that the maturity of hPSC-CMs transplanted into rat hearts was improved. There are also methods to wrap hPSC-CMs with fibrin hydrogel to form a 3D structure, use a mold to stretch and assist contraction, and give a certain regular electrical stimulation. hPSC-CMs show characteristics such as gene expression profiles, sarcomere structures, and metabolic patterns that are closer to adult myocardium. However, the 3D method is complicated to operate, which is not conducive to subsequent large-scale experimental operations to achieve mass production of cardiomyocytes. Therefore, researchers in this field are still looking forward to a method of inducing cardiomyocyte differentiation and maturation that has a more ideal degree of differentiation and is convenient for subsequent mass production. Summary of the invention
[0004] In order to improve the above technical problems, the present invention provides a method for inducing cardiomyocyte differentiation and maturation using granulocyte colony stimulating factor (G-CSF), wherein the expression level of genes related to cardiomyocyte maturation in the induced cardiomyocytes is increased, and the differentiated and mature cardiomyocytes can be used as a cell therapy agent for preventing or treating heart disease.
[0005] The present invention provides a method for inducing myocardial cell differentiation and maturation using granulocyte colony stimulating factor (G-CSF);
[0006] Preferably, the cardiomyocytes are cardiomyocytes induced from stem cells (e.g., pluripotent stem cells);
[0007] Preferably, the pluripotent stem cells are human pluripotent stem cells;
[0008] Preferably, the human pluripotent stem cells include human embryonic stem cells and human induced pluripotent stem cells.
[0009] In some embodiments, the concentration of granulocyte colony stimulating factor (G-CSF) is 0.1-100 ng / mL, preferably 20-100 ng / mL, more preferably 20-50 ng / mL, and even more preferably 20 ng / mL.
[0010] In some embodiments, the time for inducing cardiomyocyte differentiation and maturation using granulocyte colony stimulating factor (G-CSF) is selected from day 19 to day 23 (D19-D23), day 23 to day 27 (D23-D27) or day 19 to day 27 (D19-D27) of cardiomyocyte differentiation, preferably day 19 to day 27 (D19-D27).
[0011] In some embodiments, the method comprises culturing cardiomyocytes, preferably differentiated cardiomyocytes, in a medium supplemented with granulocyte colony stimulating factor (G-CSF).
[0012] In some embodiments, the method comprises the following steps:
[0013] (a) culturing stem cells in a differentiation medium supplemented with a GSK-3 inhibitor to induce differentiation into cardiomyocytes;
[0014] (b) continuing to induce differentiation in the differentiation medium;
[0015] (c) continuing to induce differentiation in differentiation medium supplemented with Wnt inhibitors;
[0016] (d) continuing to induce differentiation in the differentiation medium;
[0017] (e) Differentiation and maturation were induced in a medium supplemented with granulocyte colony stimulating factor (G-CSF).
[0018] In some embodiments, the method comprises the following steps:
[0019] (a) Days 0-2, stem cells were cultured in differentiation medium supplemented with GSK-3 inhibitor to induce differentiation into cardiomyocytes;
[0020] (b) After one day of induction, differentiation was continued in the differentiation medium;
[0021] (c) Days 3-5, differentiation was continued induction in differentiation medium supplemented with Wnt inhibitors;
[0022] (d) Day 5-15, continue to induce differentiation in differentiation medium;
[0023] (e) On days 15-27, differentiation and maturation were induced in a medium supplemented with granulocyte colony stimulating factor (G-CSF).
[0024] In some embodiments, the differentiation medium in steps (a), (b), (c), and (d) comprises PRMI1640 basal medium and B27 supplement without insulin;
[0025] And / or, the culture medium in step (e) comprises PRMI1640 basal medium and B27 supplement containing insulin.
[0026] In some embodiments, the GSK-3 inhibitor is selected from CHIR99021;
[0027] And / or, the Wnt inhibitor is selected from any one, two or more of IWR-1, IWP-2, IWP-4 and C59.
[0028] In some embodiments, the concentration of the GSK-3 inhibitor is 0.5 μM-10 μM, preferably 6 μM;
[0029] And / or, the concentration of the Wnt inhibitor is 0.5 μM-20 μM, preferably 2 μM.
[0030] In some embodiments, in step (a), when the cardiomyocytes grow to a confluence of 85-98% (eg, 95%), the culture medium is changed to a differentiation medium to induce differentiation.
[0031] In some embodiments, spontaneously beating cells can be observed on day 9 in step (d).
[0032] In some embodiments, the time for inducing differentiation and maturation in step (e) is selected from day 19 to day 23 (D19-D23), day 23 to day 27 (D23-D27), day 19 to day 27 (D19-D27), preferably day 19 to day 27 (D19-D27).
[0033] In some embodiments, stem cells include pluripotent stem cells, multipotent stem cells, and unipotent stem cells.
[0034] In some embodiments, the stem cells are human pluripotent stem cells, such as human embryonic stem cells, human induced pluripotent stem cells.
[0035] In some embodiments, granulocyte colony stimulating factor (G-CSF) increases the expression level of at least one gene or protein selected from the group consisting of: TNNT2 (cardiac troponin T), TNNI3 (cardiac troponin I), SERCA2a (calcium ATPase 2a), RYR2 (human ryanodine receptor 2), KCNQ1 (potassium ion channel protein), KCNH2 (potassium voltage-gated channel subfamily H member 2), β-MHC (cardiac myosin heavy chain subunit), CACNA1c (calcium voltage-gated channel subunit alpha1 C), LDHA (lactate dehydrogenase A) in differentiated cardiomyocytes.
[0036] In some embodiments, granulocyte colony stimulating factor (G-CSF)-induced secretion of vascular endothelial growth factor (VEGF) by differentiated mature cardiomyocytes is increased.
[0037] The present invention provides a use of granulocyte colony stimulating factor (G-CSF) in preparing a product for inducing myocardial cell differentiation and maturation.
[0038] In some embodiments, the product is selected from a reagent, a composition, a culture medium, and the like.
[0039] The present invention provides a culture medium for inducing cardiomyocyte maturation and differentiation, the culture medium comprising a basal culture medium and granulocyte colony stimulating factor (G-CSF);
[0040] Preferably, the concentration of granulocyte colony stimulating factor (G-CSF) in the basal culture medium is 20-50 ng / mL, more preferably 20 ng / mL.
[0041] In some embodiments, the basal culture medium is selected from PRMI1640 culture medium, mTESR1 culture medium, etc.; more preferably, it is PRMI1640 culture medium supplemented with insulin B27.
[0042] The present invention provides a cell therapy agent for preventing or treating heart disease, wherein the cell therapy agent comprises differentiated mature myocardial cells prepared by the above method.
[0043] In some embodiments, the cardiac disease may be at least one selected from the group consisting of, but not limited to: myocardial infarction, angina pectoris, ischemic cardiomyopathy, primary cardiomyopathy, secondary cardiomyopathy, and heart failure.
[0044] Beneficial Effects
[0045] This study showed that granulocyte colony stimulating factor (G-CSF) can effectively promote the maturation of cardiomyocytes in 2D culture conditions. At the same time, the expression of genes related to the function of mature cardiomyocytes was significantly increased. BRIEF DESCRIPTION OF THE DRAWINGS
[0046] Figure 1 Schematic diagram of the process of hiPSCs-CMs differentiation, culture and compound treatment.
[0047] Figure 2 The expression trends of myocardial-related genes under different treatments to induce myocardial cell maturation are shown. The myocardial-related genes are TNNT2, TNNI3, SERCA2a, RYR2, KCNQ1, KCNH2, β-MHC, CACNA1c, and LDHA. The horizontal axes in the fluorescence quantitative PCR graph are negative control, scheme 1, scheme 2, scheme 3, scheme 4, and scheme 5.
[0048] Figure 3 Under different treatments for inducing cardiomyocyte maturation, after induction with granulocyte colony stimulating factor (G-CSF), the positive rate of CTNT did not change significantly, indicating that the addition of granulocyte colony stimulating factor (G-CSF) would not affect the positive rate of cardiomyocyte differentiation. The horizontal axes in the figure are negative control, scheme 1, scheme 2, scheme 3, scheme 4, and scheme 5.
[0049] Figure 4 The increase in the amount of VEGF secreted by cardiomyocytes under different treatments to induce cardiomyocyte maturation. The horizontal axes in the figure are negative control, scheme 1, scheme 2, scheme 3, scheme 4, and scheme 5.
[0050] Figure 5 This is the recovery effect of cardiomyocytes before and after maturation on the cardiac function of mice under the treatment process of inducing cardiomyocyte maturation in scheme 3.
[0051] Explanation of terms
[0052] hiPSCs-CMs: cardiomyocytes induced from hiPSC cells.
[0053] TNNT2: Cardiac troponin T. The protein encoded by this gene is the troponin binding subunit of the troponin complex, located on the thin filaments of striated muscle, and regulates muscle contraction through changes in intracellular calcium ion concentration. Mutations in this gene are associated with familial hypertrophic cardiomyopathy and dilated cardiomyopathy.
[0054] TNNI3: Cardiac Troponin I, cardiac TNNI3 is a protein that in humans is encoded by the TNNI3 gene. It is a tissue-specific isoform of troponin I, which in turn is part of the troponin complex. The TNNI3 gene encoding cardiac troponin I (cTnI) is located at 19q13.4 in the human chromosome genome.
[0055] SERCA2a: Calcium ion ATPase 2a, sarcoplasmic reticulum / endoplasmic reticulum ATPase 2a (SERCA2a) is the main calcium pump for sarcoplasmic reticulum to recycle calcium ions in myocardial cells. It transports calcium ions from the cytoplasm to the lumen of the sarcoplasmic reticulum by consuming ATP. SERCA2a is essential for maintaining calcium homeostasis and cardiac function in myocardial cells, and changes in its activity and expression are closely related to the occurrence and development of heart failure.
[0056] RYR2: Human ryanodine receptor 2Ryanodine receptor (RyR2) is a calcium ion release channel located on the sarcoplasmic reticulum of cardiomyocytes. As an important component of myocardial excitation-contraction coupling, RyR2 dysfunction plays a key role in the occurrence and progression of many heart diseases. Catecholamine-sensitive polymorphic ventricular tachycardia (CPVT) is associated with RyR2 gene mutations.
[0057] KCNQ1: Also known as Kv7.1, is a voltage-dependent K+ channel that regulates gastric acid secretion, salt and glucose homeostasis, and heart rhythm. Its functional properties are regulated in a tissue-specific manner by co-assembly with the β subunits KCNE1-5. In non-excitable cells, KCNQ1 forms a complex with KCNE3, which inhibits channel closure at negative membrane voltages, which would otherwise be closed. Pore opening is regulated by the signaling lipid PIP2.
[0058] KCNH2: This gene encodes a component of a voltage-activated potassium channel found in cardiac muscle, neurons, and microglia. Four copies of this protein interact with one copy of the KCNE2 protein to form a functional potassium channel. Mutations in this gene can cause long QT syndrome type 2 (LQT2). Transcript variants encoding different isoforms have been identified.
[0059] β-MHC: Encoded by the Myh7 gene, which is located on mouse chromosome 14. It is a hexameric protein containing 2 heavy chain subunits, 2 basic light chain subunits, and 2 regulatory light chain subunits. This gene encodes the β heavy chain subunit of cardiac myosin. It is mainly expressed in the ventricles of normal people, and is also expressed in skeletal muscle tissue rich in type I slow muscle fibers. The relative abundance of this protein and changes in the α heavy subunit of cardiac myosin are related to the contraction speed of the myocardium.
[0060] CACNA1c: CACNA1C (Calcium Voltage-Gated Channel Subunit Alpha1 C) is a protein-coding gene. This gene encodes the alpha-1 subunit of the voltage-dependent calcium channel. Calcium channels mediate the influx of calcium ions into the cell upon membrane polarization. The alpha-1 subunit consists of 24 transmembrane segments that form a pore through which ions enter the cell. The calcium channel is composed of a complex of alpha-1, alpha-2 / delta, beta, and gamma subunits in a 1:1:1:1 ratio. Diseases associated with CACNA1C include Timothy syndrome and Long Qt syndrome8.
[0061] LDHA: This gene encodes a protein that catalyzes the conversion of L-lactate and NAD to pyruvate and NADH in the final step of anaerobic glycolysis. This protein is primarily found in muscle tissue and belongs to the lactate dehydrogenase family. Mutations in this gene are associated with exertional myoglobinuria. Multiple transcript variants encoding different isoforms have been found for this gene. The human genome contains several non-transcribed pseudogenes of this gene.
[0062] Stem cell: It is a cell that constitutes the basis of the cells or tissues of the object, and refers to a cell with pluripotency, which is characterized by that it can self-renew by repeated division, and can differentiate into cells with specific functions according to the environment. Stem cells can be divided into pluripotent stem cells, multipotent stem cells and unipotent stem cells according to their differentiation ability. Pluripotent stem cells are pluripotent cells with the potential to differentiate into all cells (omnipotent). Human pluripotent stem cells (Human pluripotent stem cells, hPSC) include embryonic stem cells (Embryonic stem cell, ESCs) and induced pluripotent stem cells (induced pluripotent stem cell, iPSCs), etc. In the present invention, the stem cell can be a pluripotent stem cell, and can preferably be a human pluripotent stem cell, but is not limited thereto.
[0063] Cardiomyocytes: include but are not limited to myocardial precursor cells that have the ability to become functional myocardial cells in the future, or fetal myocardial cells, cells at all differentiation stages of adult myocardial cells, which refers to cells that can be identified by at least one, preferably multiple markers or standards by at least one, preferably multiple of the following methods. The expression of various markers specific to myocardial cells can be detected by known biochemical methods or immunochemical methods, and these methods can be used without restriction. In this method, polyclonal antibodies or monoclonal antibodies that are specific to markers that bind to myocardial precursor cells or myocardial cells can be used. Without limitation, antibodies targeting a single specific marker can be commercially available or prepared by known methods.
[0064] Cell therapy agents: refer to cells and tissues prepared by separation, culture and special operations from humans. They are drugs used for treatment, diagnosis and prevention purposes (as stipulated by the US FDA). They also refer to drugs used for treatment, diagnosis and prevention purposes through a series of actions, such as proliferating and selecting living autologous, allogeneic or xenogeneic cells in vitro or otherwise changing the biological characteristics of cells to restore the function of cells or tissues.
[0065] Prevention: refers to any action of inhibiting or delaying the progression of heart disease by administering the cell therapeutic agent according to the present invention.
[0066] Treatment: refers to any effect of improving or beneficially changing a heart disease by administering a cell therapy agent according to the present invention. DETAILED DESCRIPTION
[0067] The technical scheme of the present invention will be further described in detail below in conjunction with specific embodiments. It should be understood that the following embodiments are only exemplary descriptions and explanations of the present invention and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are included in the scope that the present invention is intended to protect.
[0068] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods.
[0069] Example 1 Induction of iPSC-derived cardiomyocytes
[0070] hiPSCs (using the kit CTS TM CytoTune TM -iPS 2.1Sendai Reprogramming Kit, Catalog No.: A34546) was grown to about 95% confluency, and hiPSC cells were washed with DPBS, and then 1 mL of ethylenediaminetetraacetic acid digestion solution (versene, 0.02% EDTA solution) was added and digested at 37°C for 5 min. The digestion solution was aspirated, and the digested cells were blown into single cells with 1 mL of mTeSR1 medium containing 10 μM Y-27632 (purchased from Tocris, Catalog No. TB1254-GMP), and then counted and counted at 2×10 5The cells were seeded at a density of 100 cells / well in a matrigel-coated 12-well cell culture plate, which was recorded as the -2 day of induction. On the -1 day, fresh mTeSR1 medium without Y-27632 was used to continue culture for 1 day. On the 0th day of induction, when the cells grew to about 95% confluence, the medium was changed to cardiomyocyte differentiation medium for induction. On the 0th day of induction, 6μM CHIR99021 (purchased from Tocris, catalog number TB4423-GMP) was added to the culture medium. After 1 day of induction, fresh differentiation medium was replaced. On the 3rd to 5th day of induction, 2μM IWR-1 (purchased from tocris, catalog number 3532) was added to the culture medium. On the 5th day, fresh differentiation medium was replaced and the medium was replaced every two days. Spontaneous beating cells can be observed on the 9th day of induction. On the 15th day of differentiation, the culture medium was discarded, and 500μL accutase was added to each well and digested at 37℃ for 5-6min. Use a pipette to blow the cells and collect the cell suspension. Then rinse the wells with differentiation medium to collect the remaining cells. Then filter the cell suspension with a 70-mesh nylon filter and centrifuge at 200g for 5 minutes. Resuspend the cell pellet with cardiomyocyte maintenance medium and add 4×10 5 The cells were seeded at a density of 100 cells / well in a matrigel-coated 12-well plate and cultured, with the medium changed every two days. hiPSCs-CMs cells were obtained, and the hiPSCs-CMs cardiomyocyte induction process was as follows Figure 1 shown.
[0071] Figure 1 It includes the culture of embryonic stem cells, the time interval of differentiation, culture, purification and compound treatment of cardiomyocytes, the culture medium, additives and compounds used, and the corresponding operations. Day -2 to day 0 is the hiPSCs culture stage, and the culture medium used is mTESR1; Day 0-15 is the cardiomyocyte induction stage, and the culture medium used is PRMI1640 with B27 without insulin, and the cells are induced with GSK3 inhibitor CHIR99021 and Wnt inhibitor IWR-1 respectively; Day 15-30 is the cardiomyocyte maintenance stage, and the culture medium used is PRMI1640 with B27 with insulin; Day 19-27 treats the cells with G-CSF (purchased from R&D, catalog number 214-CS-025 / CF).
[0072] Example 2 Induced cardiomyocyte maturation
[0073] In order to promote the maturation of hiPSCs-CMs, 5 dosing intervals and concentrations were set up to test the maturity. hiPSCs were plated in a culture dish, and when they grew to more than 95% full, myocardial induction differentiation was started according to Example 1. The hiPSCs-CMs cells obtained by differentiation were induced to mature myocardial cells according to the following table.
[0074] Table 1 Five different dosing time periods and concentrations
[0075] Setting Mode Time period of drug administration G-CSF concentration Scheme1 D19-D23 20 ng / mL Scheme2 D23-D27 20 ng / mL Scheme3 D19-D27 20 ng / mL Scheme4 D19-D23 50ng / mL Scheme5 D19-D27 100ng / mL
[0076] Effect Example 1 Fluorescence quantitative PCR comparison of the expression of myocardial cell-related genes
[0077] Using hiPSCs-CMs cells prepared in different maturation modes of Example 2, quantitative analysis of myocardial expression cell-related genes was performed as follows: aspirate the culture medium, wash once with PBS, add 500 μL Trizol to each well of the 12-well plate to lyse the cells, and collect the cell lysate into an RNase free 1.5 mL EP tube. Add 100 μL chloroform to each tube, vortex oscillator vigorously oscillates for 15 s, let stand at room temperature for 5 min, and centrifuge at 4°C 12000g for 15 min. Carefully draw the upper liquid into a new RNase free 1.5 mL EP tube, add an appropriate amount of isopropanol, gently turn upside down 6 times, let stand at room temperature for 10 min, and centrifuge at 4°C 12000g for 10 min. Remove the supernatant, add 500 μL pre-cooled 75% ethanol to rinse, and centrifuge at 4°C 7500g for 5 min. Remove as much ethanol as possible, dry it open for 5 min, add 15-20 μL DEPC water and place it on ice. After the RNA is dissolved, the RNA concentration is measured using a Nano Drop concentration meter. TM Prepare the reaction system on ice according to the instructions of the RT Master Mix kit.
[0078] Reaction system (20 μL):
[0079]
[0080] Reaction procedure:
[0081]
[0082] The obtained cDNA can be stored at -20°C.
[0083] The fluorescence quantitative PCR reaction system was prepared using 2×SYBR Green qPCR Master Mix reagent.
[0084] Reaction system (20 μL):
[0085]
[0086]
[0087] Primer Table
[0088] Primers sequence TNNT2-F CTGCTGTTCTGAGGGAGAGC TNNT2-R CACCAAGTTGGGCATGAACG TNNI3-F TTTGACCTTCGAGGCAAGTTT TNNI3-R CCCGGTTTTCCTTCTCGGTG MYH7-F ACCTGTCCAAGTTCCGCAAG MYH7-R TCATTCAAGCCCTTCGTGCC RYR2-F TCCGGAAACAGTATGAAGACCA RYR2-R CACACAACGCTGGCAATTCA SERCA2-F ACCTGGAACCTGTTCTTAGCTC SERCA2-R CATCACAGATGACAATTAGTGCC CACNA1c-F CATGCTCACGGTGTTCCA CACNA1c-R TCCTACGGCATCATTGACC KCNH2-F TGTCACGGATGAATGCCCAA KCNH2-R CTGCGCCAATGATGAAAGCA LDHA-F GACTTCTGAGGAAGAGGCCC LDHA-R CATGCACAACCTCCACCTAGA KCNQ1-F TGTCCACCATCGAGCAGTATG KCNQ1-R CCGTCCCGAAGAACACCAC GAPDH-F AGATCCCTCCAAAATCAAGTGG GAPDH-R GGCAGAGATGATGACCCTTTT
[0089] Reaction procedure:
[0090]
[0091] According to the Ct value given by the software, the difference in mRNA expression fold of the samples was calculated using the △△Ct algorithm.
[0092] The degree of myocardial cell maturity can be characterized by detecting genes related to myocardial cell maturation. For example, myocardial cell sarcomere structure-related genes TNNT2, TNNI3, β-MHC (cardiac myosin heavy chain subunit), potassium ion channel proteins KCNQ1, KCNH2, calcium voltage-gated channel protein CACNA1c, sarcoplasmic reticulum calcium ion transporters RYR2 and SERCA2a, and lactate dehydrogenase LDHA are all typical markers of myocardial cell maturation, which are expressed at very low levels in immature myocardium and significantly increased in mature myocardial cells.
[0093] Fluorescence quantitative PCR showed that the expression of related genes in hiPSCs-CMs treated with granulocyte colony stimulating factor (G-CSF) was significantly enhanced, indicating that granulocyte colony stimulating factor (G-CSF) can promote the maturation of hiPSCs-CMs by increasing the expression of cardiomyocyte genes. For details, see Figure 2 According to the expression of cardiomyocyte-specific genes, the Scheme 3 setting mode has a significant effect on promoting the increase of the expression of genes related to the myometrial structure of cardiomyocytes, such as TNNT2, TNNI3, β-MHC (cardiac myosin heavy chain subunit), potassium channel proteins KCNQ1, KCNH2, calcium voltage-gated channel protein CACNA1c, sarcoplasmic reticulum calcium transporter RYR2 and SERCA2a, lactate dehydrogenase LDHA, etc. Therefore, it is planned to add 20 ng / mL of G-CSF on D19-D27 in the future.
[0094] Effect Example 2 Immunofluorescence staining flow cytometry
[0095] After 30 days of differentiation, hiPSCs-CMs cells were digested with accutase, the cell suspension was collected, and the cells were washed with PBS after centrifugation. Then, they were fixed with 4% PFA at room temperature for 30 minutes, and then blocked with antibodies and incubated at room temperature for 10 minutes. After the primary antibody was diluted according to the instructions, it was added to the cells and incubated at room temperature for 1 hour, then washed twice with PBS, and after washing away the non-specifically bound primary antibody, the cells were analyzed by flow cytometry. The results showed that the proportion of cTnt+ cells in the DMSO control group was 92.27%, and the proportion of cTnt+ cells in the granulocyte colony stimulating factor (G-CSF) treatment group was 90.82-97.62%. Compared with the control group, granulocyte colony stimulating factor (G-CSF) treatment did not significantly change the purity of cardiomyocytes.
[0096] In summary, G-CSF can promote the expression of mature myometrium and the percentage of ventricular myocardium in hiPSCs-CMs without changing the cell differentiation efficiency (e.g. Figure 3 ).
[0097] Effect Example 3
[0098] After culturing the differentiated cardiomyocytes for 30 days in serum-free medium for 48 hours, the cell supernatant was collected for ELISA quantitative VEGF detection. The test results showed that the addition of G-CSF could significantly promote the increase of VEGF expression (e.g. Figure 4 ).
[0099] Effect Example 4
[0100] Myocardial infarction (MI) and acute coronary heart disease are among the most prominent causes of death in cardiovascular diseases. The MI mouse model with permanent ligation of the left anterior descending (LAD) coronary artery is very similar to human MI. The mouse surgical model of myocardial infarction by permanent LAD coronary artery ligation is highly reproducible and is currently the most widely used method for making a mouse myocardial infarction model, providing a stable model basis for subsequent product efficacy verification. After the MI model is successfully made, blood flow in most of the left ventricle myocardium stops. Insufficient myocardial oxygen supply can lead to ischemic death of cardiomyocytes. This pathological condition triggers a response in the ventricular tissue, ultimately leading to ventricular dysfunction, remodeling, and heart failure.
[0101] Modeling of permanent ligation of the left anterior descending coronary artery in mice: The mice were weighed to determine the dose of anesthetic drugs and the tidal volume of the ventilator. The mice were anesthetized by intraperitoneal injection of 1.25% tribromoethanol at a dose of 10 μL / g. The anesthetized mice were taken, the chest was opened between the 3rd and 4th intercostal spaces to expose the heart, and the left anterior descending coronary artery was permanently ligated at about 2 mm below the lower edge of the left atrial appendage with a 7-0 suture needle to create a mouse model of acute myocardial infarction.
[0102] Sham-operated mice: Anesthetized mice were taken, and the heart was exposed by opening the chest between the 3rd and 4th intercostal space. A 7-0 suture needle was used to thread the left atrial appendage approximately 2 mm below the lower edge, without ligating the left anterior descending coronary artery.
[0103] Four days after modeling, a second thoracotomy was performed, and cells were injected at three points around the infarct, with an injection volume of about 5-10 μL at each point and a total of about 2 million cells. Two months after cell injection, cardiac ultrasound function testing was performed. Echocardiography can be used to evaluate cardiac structure and function in vivo. Related measurements include left ventricular wall thickness, inner diameter, mass, shortening fraction, and ejection fraction. After anesthetizing the chest and abdomen of the mouse, the specific operations were as follows:
[0104] The left ventricle was imaged in B-mode in the parasternal long axis view. The mouse ultrasound stage was carefully adjusted to position the long axis of the left ventricle in the same plane as the ultrasound beam, and the aortic valve and the apex of the left ventricle were placed in the same plane as the ultrasound beam when the image was taken. The aortic valve and the apex of the left ventricle served as fixed points and remained unchanged between serial studies in the same animal. The left ventricle was subjected to M-mode to image the ventricular wall and interior. After imaging, the points were taken according to the maximum amplitude of ventricular contraction and relaxation to calculate the relevant characteristic values: ejection fraction EF%, left ventricular wall shortening fraction FS%, left ventricular end-systolic volume LV Vol,S, and left ventricular end-diastolic volume LV Vol,D.
[0105] The efficacy of the drug in myocardial infarction mice was evaluated using cardiomyocytes differentiated for about 30 days, and the efficacy of cardiomyocytes added with 20ng / mL G-CSF (Scheme 3) in the treatment of myocardial infarction was compared. There were 4 sham-operated mice, 14 vehicle-treated mice, 11 non-G-CSF-treated cells, and 9 G-CSF-treated cells. The solvents used were 5% human albumin and 95% compound electrolyte solution.
[0106] Depend on Figure 5 It can be seen that after adding G-CSF, the more mature cardiomyocytes have a significant effect on the recovery of mouse heart function. Compared with the cell efficacy without adding G-CSF, the EF value increased from 30.1 to 33.6, the FS value increased from 14.0 to 15.9, the end-systolic volume decreased from 54.2 to 47.5, and the end-diastolic volume decreased from 77.4 to 70.6.
[0107] The above is an explanation of the embodiments of the present invention. However, the present invention is not limited to the above embodiments. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A method for inducing cardiomyocyte differentiation and maturation using granulocyte colony stimulating factor (G-CSF).
2. The method according to claim 1, characterized in that The cardiomyocytes are cardiomyocytes induced from stem cells; Preferably, the stem cells are pluripotent stem cells; More preferably, the pluripotent stem cells are human pluripotent stem cells; Further preferably, the human pluripotent stem cells include human embryonic stem cells and human induced pluripotent stem cells.
3. The method according to claim 1 or 2, characterized in that: The concentration of granulocyte colony stimulating factor (G-CSF) is 0.1-100 ng / mL, preferably 20-100 ng / mL, more preferably 20-50 ng / mL; And / or, the time for inducing cardiomyocyte differentiation and maturation using granulocyte colony stimulating factor (G-CSF) is selected from day 19 to day 23 (D19-D23), day 23 to day 27 (D23-D27) or day 19 to day 27 (D19-D27) of cardiomyocyte differentiation, preferably day 19 to day 27 (D19-D27).
4. The method according to any one of claims 1 to 3, characterized in that: The method comprises culturing cardiomyocytes, preferably differentiated cardiomyocytes, in a medium supplemented with granulocyte colony stimulating factor (G-CSF); More preferably, the method comprises the following steps: (a) culturing stem cells in a differentiation medium supplemented with a GSK-3 inhibitor to induce differentiation into cardiomyocytes; (b) continuing to induce differentiation in the differentiation medium; (c) continuing to induce differentiation in differentiation medium supplemented with Wnt inhibitors; (d) continuing to induce differentiation in the differentiation medium; (e) inducing differentiation and maturation in a medium supplemented with granulocyte colony stimulating factor (G-CSF); Further preferably, the method comprises the following steps: (a) Days 0-2, stem cells were cultured in differentiation medium supplemented with GSK-3 inhibitor to induce differentiation into cardiomyocytes; (b) After one day of induction, differentiation was continued in the differentiation medium; (c) Days 3-5, differentiation was continued induction in differentiation medium supplemented with Wnt inhibitors; (d) Day 5-15, continue to induce differentiation in differentiation medium; (e) On days 15-27, differentiation and maturation were induced in a medium supplemented with granulocyte colony stimulating factor (G-CSF).
5. The method according to claim 4, characterized in that The differentiation medium in steps (a), (b), (c) and (d) comprises PRMI1640 basal medium and B27 supplement without insulin; And / or, the culture medium in step (e) comprises PRMI1640 basal medium and B27 supplement containing insulin; and / or, the GSK-3 inhibitor is selected from CHIR99021; and / or, the Wnt inhibitor is selected from any one, two or more of IWR-1, IWP-2, IWP-4, and C59; and / or, the concentration of the GSK-3 inhibitor is 0.5 μM-10 μM, preferably 6 μM; and / or, the concentration of the Wnt inhibitor is 0.5 μM-20 μM, preferably 2 μM; and / or, in step (a), when the cardiomyocytes grow to a confluence of 85-98% (e.g., 95%), the culture medium is replaced with a differentiation medium to induce differentiation; And / or, the time for inducing differentiation and maturation in step (e) is selected from day 19 to day 23 (D19-D23), day 23 to day 27 (D23-D27), day 19 to day 27 (D19-D27), preferably day 19 to day 27 (D19-D27).
6. The method according to claim 4 or 5, characterized in that: Stem cells include pluripotent stem cells, multipotent stem cells and unipotent stem cells; Preferably, the stem cells are human pluripotent stem cells, such as human embryonic stem cells, human induced pluripotent stem cells.
7. The method according to any one of claims 1 to 6, characterized in that: Granulocyte colony stimulating factor (G-CSF) increases the expression level of at least one gene or protein selected from the group consisting of: TNNT2 (cardiac troponin T), TNNI3 (cardiac troponin I), SERCA2a (calcium ATPase 2a), RYR2 (human ryanodine receptor 2), KCNQ1 (potassium channel protein), KCNH2 (potassium voltage-gated channel subfamily H member 2), β-MHC (cardiac myosin heavy chain subunit), CACNA1c (calcium voltage-gated channel subunit alpha1 C), LDHA (lactate dehydrogenase A) in differentiated cardiomyocytes; and / or, granulocyte colony stimulating factor (G-CSF)-induced increase in secretion of vascular endothelial growth factor (VEGF) by differentiated mature cardiomyocytes.
8. Use of granulocyte colony stimulating factor (G-CSF) in the preparation of products for inducing myocardial cell differentiation and maturation; Preferably, the product is selected from a reagent, a composition, a culture medium and the like.
9. A culture medium for inducing cardiomyocyte maturation and differentiation, the culture medium comprising a basal culture medium and granulocyte colony stimulating factor (G-CSF); Preferably, the concentration of granulocyte colony stimulating factor (G-CSF) in the basal medium is 20-50 ng / mL, more preferably 20 ng / mL; Preferably, the basal culture medium is selected from PRMI1640 culture medium, mTESR1 culture medium, etc.; more preferably, it is PRMI1640 culture medium supplemented with insulin B27.
10. A cell therapy agent for preventing or treating heart disease, the cell therapy agent comprising differentiated mature cardiomyocytes prepared by the method according to any one of claims 1 to 7; Preferably, the heart disease may be at least one selected from the group consisting of, but not limited to: myocardial infarction, angina pectoris, ischemic cardiomyopathy, primary cardiomyopathy, secondary cardiomyopathy and heart failure.
Citation Information
Patent Citations
Transduced peptide-humanized granular leukocyte colony stimulating factor fusion protein and its medicinal composition
CN101074266A
Method of inducing differentiation into myocardial cells using g-csf
CN101720355A
Method for acquiring stem cell-derived myocardial cells based on Rbm24 gene
CN106591318A
Method for promoting maturation of myocardial cells differentiated from multipotential stem cells
CN108060125A
Inducing method for promoting directional differentiation of multipotential stem cells into myocardial cells
CN108359636A
